High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients

Xiaomin Zhang,1 Fu’an Wang,1 Guangfeng Gu,2 and Qingpo Wu2

1Department of Clinical Medicine, Pingdingshan University, Weilai Road, Xincheng District, Pingdingshan, Henan 467000, China
2Department of Cardiology, The First People’s Hospital of Pingdingshan, Youyu Road, Pingdingshan, Henan 467000, China

Correspondence should be addressed to Xiaomin Zhang; xiaomin23123@126.com

Received 26 March 2021; Revised 26 May 2021; Accepted 3 June 2021; Published 12 June 2021

Academic Editor: Nicola Silvestris

Copyright © 2021 Xiaomin Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. MiR-122 is a liver-specific microRNA. The aim of the study was to explore the association of serum miR-122 with response to sorafenib in hepatitis B virus-(HBV-) related hepatocellular carcinoma (HCC) patients and to further reveal the effect of the virus load on such potential relationship. Methods. A total of 588 patients with HCC were retrospectively included. All of them were diagnosed with HBV-related locally advanced HCC and were treated with sorafenib. Therapeutic and prognostic information and other information were collected from medical records. Stored blood specimens that were obtained before sorafenib treatment were adopted to detect miR-122. Results. Patients were divided into high-level group and low-level group according to the median of serum miR-122 level, and each group contained 294 patients. During the first 24 weeks after sorafenib treatment, the patients in the high-level group had more opportunities to experience progression-free survival (PFS) and overall survival (OS) than those in the low-level group (HR: 2.47, 95%CI: 1.24–4.88; HR: 1.20, 95%CI: 1.09–1.32). In the subgroup analysis, the relationship between serum miR-122 level and overall survival still existed in the patients with relatively lower HBV load (HR: 1.22, 95%CI: 1.09–1.36), but not in the patients with higher HBV load (HR: 1.12, 95%CI: 0.93–1.35). Conclusion. Higher serum level of miR-122 at baseline was associated with a better response to sorafenib in HBV-related locally advanced HCC patients, and relatively high HBV load weakened such predictive effect mentioned above.

1. Introduction

Hepatocellular carcinoma (HCC) is the dominant type of primary liver cancer in human beings, accounting for about 90% of total cases all around the world [1]. In China, HCC is a very common cancer with an estimated incidence rate of 0.40‰ in males and 0.15‰ in females [2]. Also in this country, the major cause of cancer is hepatitis B virus (HBV) infection, not long-term drinking [2]. HCC is a malignant disease with poor prognosis. Previous studies reported that the expected median survival period of the patients does not exceed five months without treatment [3, 4]. In the last decade or two, diagnostic technology is developing rapidly and allows more than 50% of the patients to be confirmed at a locally advanced stage. This provides a valuable opportunity for early intervention against HCC.

Sorafenib (SOR) is an oral molecule-targeted drug against malignancies which is introduced in 2007. Clinical trials report that SOR significantly increases the median overall survival (OS) of HCC patients [5, 6]. However, not all patients are sensitive to the drug, and the response to SOR has become one of the most important factors affecting the efficacy of SOR and the prognosis of the patients. To date, studies have reported many potential predictors of SOR response, such as proteins, cell-free DNA, microRNA, and inflammatory markers, but their predictive power is unsatisfactory or not fully confirmed [7–9]. Therefore, unlike other targeted therapies, available predictors in HCC patients treated with SOR are lacking, and related research is still ongoing.
MicroRNA-122 (miR-122) is a liver-specific microRNA. Tissue expression of it can be changed in many liver diseases [10]. MiR-122 has also been discovered in peripheral circulation, and an increased level of miR-122 in serum is associated with the progression of viral hepatitis, nonalcoholic fatty liver disease, and other liver injuries [11–13]. During in vitro experiments, downregulation of miR-122 has been found in HCC, and reactivation of miR-122 can help increase sensitivity of HCC to SOR [14, 15]. So, we believe that miR-122 might be a promising predictor for SOR response in HCC patients.

Taken together, we conducted a retrospective cohort study including hundreds of HBV-related HCC patients with SOR treatment to explore the predictive significance of miR-122 in SOR response and to further reveal the potential effect of the main confounding factor (i.e., HBV load) on such relationship in the patients.

## 2. Materials and Methods

### 2.1. Ethical Principles. The study was approved by the ethics committees of Pingdingshan University and the First People’s Hospital of Pingdingshan. All subjects or their families agreed to participate in the study and signed written informed consent forms.

### 2.2. Patients. This study was part of a local HCC research project. All patients who agreed to participate in the project provided their peripheral blood specimens and medical records for scientific research.

Patients with HCC in the First People’s Hospital of Pingdingshan between January 2016 and June 2020 were retrospectively included in the study. The included patients should be diagnosed with HBV-related HCC according to American Association for the Study of Liver Diseases criteria [16] and received SOR treatment with a standard dose of 800 mg daily (400 mg, twice a day) for the first time. Before the SOR treatment, the patients should also meet the following criteria: (1) Baseline age ≥ 18 years old. (2) Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 [17]. (3) Child-Pugh classification of A [18]. (4) Absence of hepatitis C, severe fatty liver, or alcoholic liver disease. (5) Presence of macroscopic vascular invasion according to CT scan. (6) Absence of bile duct invasion and distant metastasis according to CT scan and bone scan. (7) Absence of refractory ascites, gastrointestinal hemorrhage, hepatic encephalopathy, or coagulation disorder (INR > 1.5). (8) Absence of other cancers.

A total of 601 HCC patients with SOR treatment completely met the inclusion criteria. Due to no blood specimens and refusal to participate in the study, 13 patients were excluded. So, the remaining 588 patients were included in the study (Figure 1).

In addition, the study enrolled 588 age- and gender-matched healthy controls in 2020 from the Department of Physical Examination in the same hospital. These controls did not have any liver diseases and other confirmed chronic diseases.

### 2.3. Data Collection. Demographic, serological, pathological, and imaging data of the HCC patients were collected from medical records by a group of well-trained investigators. Meanwhile, therapeutic (i.e., adverse event and treatment interruption) and prognostic data (i.e., HCC progression and death) were also collected.

According to the normal range of HBV-DNA in the medical records, HBV-DNA ≥ 10^5 copies/ml was defined as positive in the study.

### 2.4. Assessment of Efficacy and Outcome. Based on the data from the medical records, the efficacy of SOR and the outcome of the patients during the first 24 weeks after the beginning of the treatment were assessed using several prognostic markers, such as overall response rate, disease control rate, progression-free survival (PFS), and OS.

Progression was confirmed using two standards which were listed below. First, there was no change in the radiological aspect of a lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria [19]. Second, a patient died of HCC or its complications. RECIST criteria were listed as follows: Complete response (CR) and partial response (PR) were separately defined as the disappearance of all lesions and more than 30% decrease in the sum of all target lesions. Progressive disease (PD) was defined as at least a 20% increase in the sum of all target lesions. Stable disease (SD) was defined as the criteria between PR and PD. The overall response was the sum of CR and PR, and disease control was the sum of CR, PR, and SD.

### 2.5. Measurement of miR-122. As mentioned above, peripheral blood specimen was obtained from each patient when participating in the project. Then, the specimen was centrifugated at 12000 rpm for 10 minutes to separate the serum, and the latter was stored at −70°C for scientific research. In addition, blood specimen was also collected from the controls on admission.

The serum level of miR-122 was measured by RT-qPCR. In the process, U6 snRNA was served as an endogenous control. Forward and reverse primers of miR-122 were 5′-ACACTCCAGCTGGTGAGTGAATG-3′ and 5′-CTCAACTGGTGTCGGAGTGAATTGGCAGAGACACC-3′, respectively. Forward and reverse primers of U6 were 5′-CTCAGGTCACGTGGCAACAATG-3′ and 5′-AACGTGCTCA CGAATTTGCGTG-3′. Brief steps were as follows: First, total RNA was extracted using a ready-to-use TRIzol™ Reagent (Thermo Fisher Scientific). Second, the obtained RNA was transcribed into cDNA using a Hairpin-it™ miRNA or U6 snRNA Normalization Real-time RT-PCR Quantitation Kit (GenePharma). Third, a number of PCR cycles were conducted, and each cycle consisted of three steps: denaturation (95°C for 180 seconds), annealing (62°C for 30 seconds), and elongation (72°C for 30 seconds). Fourth, relative levels of miR-122 in serum were expressed using 2^{-ΔΔCt} method.
2.6. Statistical Analysis. First, the normality of continuous variables in the study was checked by the Shapiro–Wilk test. All the obtained $P$ values were larger than 0.05, which indicated that the continuous variables in the study conformed to normal distribution.

Second, the continuous variable in the study was shown as mean and standard deviation, and the difference between the two variables was measured using an independent sample $t$-test. For the categorical variable, it was expressed as frequency and constituent ratio, and the difference between the two variables was determined using the chi-square test. In addition, the difference in PFS or OS between the groups was determined using Kaplan-Meier survival analysis. In these tests, if a $P$ value was less than 0.05, it was a statistically significant difference.

Third, the relationship between outcome and serum miR-122 level was measured by multivariate COX regression analysis. Hazard ratio (HR) and 95% confidence interval (CI) were reported. If a 95%CI did not include value one, it was statistically significant. All analysis was conducted using SPSS 17.0.

3. Results

3.1. Flow Diagram in the Study. In Figure 1, there were 601 HCC patients who met the inclusion criteria. Due to no blood specimens or refusal to join, 13 patients were excluded. The remaining 588 patients were included in the study and were divided into high miR-122 group (miR122_H group) and low miR-122 group (miR122_L group) according to the median of serum miR-122 level at baseline. All of them received SOR, but only 27 patients in the miR122_H group and 25 patients in the miR122_L group completed 24 weeks of treatment. Most of them discontinued SOR treatment due to death, disease progression, or adverse event.

3.2. Baseline Level of miR-122 in Serum. In Figure 2(a), the serum level of miR-122 was significantly lower in the HCC patients than in the controls ($P < 0.001$). The median of miR-122 in the patients was 0.61, which was the demarcation between the miR122_H and miR122_L groups. Detailed data have been included in Supplementary Table 1.

3.3. Characteristics of the Patients in the Study. In Table 1, serum $\alpha$-fetoprotein (AFP) level was higher in the miR122_L group than in the miR122_H group ($P = 0.016$). The patients in the miR122_L group had more opportunities to suffer from multiple and bilateral tumors ($P = 0.023$, respectively). Duration of SOR, overall adverse events, and serious adverse events were equally distributed between the two groups ($P = 0.294$, $P = 0.158$, and $P = 0.589$, respectively).

3.4. Radiological Response to SOR in the Study. In Table 2, at the 12th week and 24th week, overall response and disease control were more common in the miR122_H group compared with the miR122_L group (12th week: $P = 0.015$ and $P = 0.012$, respectively; 24th week: $P = 0.019$ and $P = 0.007$, respectively).

3.5. Survival Outcomes in the Study. In Figures 2(b)–2(e), similar to the radiological response, PFS and OS were higher in the miR122_H group than in the miR122_L group both at the 12th week and at the 24th week (12th week: $P < 0.001$ and $P < 0.001$, respectively; 24th week: $P < 0.001$ and $P < 0.001$, respectively).

3.6. Prognostic Significance of miR-122 in the Study. In Table 3, multivariate COX regression analyses reported that the higher level of miR-122 at baseline was associated with better
overall response, disease control, PFS, and OS at the 12th week (HR: 3.22, 95% CI: 1.19–8.64; HR: 1.48, 95% CI: 1.08–1.98; HR: 1.48, 95% CI: 1.08–1.98; HR: 1.12, 95% CI: 1.07–1.32). Also, serum level of miR-122 at baseline showed a similar relationship with these radiological and survival markers at the 24th week (HR: 8.02, 95% CI: 1.01–63.58; HR: 2.47, 95% CI: 1.24–4.88; HR: 2.47, 95% CI: 1.24–4.88; HR: 1.20, 95% CI: 1.09–1.32).

3.7. Effect of HBV Load on Predictive Effect of miR-122.
In Table 4, the patients were divided into several subgroups according to HBV-DNA or HBeAg status. In the patients with negative HBV-DNA or HBeAg, the higher level of miR-122 at baseline was associated with better 24-week OS (HR: 1.22, 95% CI: 1.09–1.36; HR: 1.25, 95% CI: 1.13–1.39).

However, in the patients with positive HBV-DNA or HBeAg, there was no significant relationship between baseline miR-122 level and 24-week OS (HR: 1.12, 95% CI: 0.93–1.35; HR: 0.99, 95% CI: 0.78–1.25).

4. Discussion
Many HCC patients suffer from macroscopic vascular invasion. It should be an intrahepatic lesion but still indicates a tendency of distant metastasis. Because extrahepatic micro-metastasis is difficult to find, single local therapy may not be enough to treat such kind of HCC. So, people have introduced several therapies including SOR. The latter is one oral systemic agent which has been adopted to treat advanced HCC for more than 10 years [20]. It is able to inhibit the development of both intrahepatic lesions and potential metastasis lesions in the body and has achieved satisfactory efficacy.

Nowadays, studies mainly focus on the details of drug usage. For example, Cabibbo et al. report that median OS and median time to radiological progression are separately 10.0 and 4.1 months in the patients with SOR treatment, which help guide doctors to replace second-line therapies in a timely manner [21]. Chen et al. compare SOR with transarterial chemoembolization (TACE) and suggest that dose-adjusted SOR may be cost-effective than TACE for advanced HCC patients, which provide a basis for doctors to improve efficacy and reduce medical costs [22].

Meanwhile, SOR resistance in HCC has always plagued scholars and doctors. Some clinical, pathological, and serological markers have been introduced to predict response to SOR [23–25]. However, they all have some inevitable disadvantages, such as inconvenient measurement and unsatisfactory specificity [23–25]. Therefore, a novel and available predictor is urgently needed for HCC patients.
As one kind of stable molecule in the body, microRNAs exert a variety of biological functions in HCC. However, the prognostic significance of microRNAs in HCC has not been clarified. One study from Yoon et al. has explored several microRNAs including miR-18a, miR-21, miR-139-5p, miR-221, miR-224, and miR-10b-3p in advanced HCC patients but reported that no single microRNA was predictive of response to SOR treatment [26]. In fact, miR-122 is a liver-specific microRNA and its expression in liver tissue far exceeds all the other microRNAs mentioned above [11]. Therefore, the present study focused on serum miR-122 and confirmed the significant relationship between concentration of miR-122 in serum and response to SOR in HCC patients. Specifically, the study revealed that a higher serum level of miR-122 at baseline predicted an about 7-fold and 1.5-fold increase separately in the probabilities of 24-week overall response and disease control under SOR treatment. Similarly, the higher miR-122 level at baseline predicted an about 150% and 20% increase separately in the possibilities of 24-week PFS and OS under SOR treatment.

It is well known that HBV infection is the most important carcinogenic factor for HCC in China [27]. The influence of SOR on host immunity in HCC stratifies by etiology [28], and a high HBV load and antiviral therapy affect the survival of patients treated with SOR [29]. So, it is necessary to explore the effect of HBV infection on prognostic significance of miR-122. In the study, we divided the patients into several subgroups according to HBeAg or HBV-DNA status. The results revealed that a significant relationship between miR-122 and survival outcomes only existed in the patients with negative HBeAg or HBV-DNA. The potential mechanism involved should be explored in future studies.

Many patients in the study were not pathologically diagnosed, which might be a potential limitation. However, HCC is one of the few cancers that can be diagnosed without pathological examination [30]. Furthermore, all the patients were confirmed according to the American Association for the Study of Liver Diseases criteria. So, we did not think that the limitation affected the conclusion.

### Table 1: Characteristics of the patients in the study.

| Baseline characteristics | miR122_H group (n = 294) | miR122_L group (n = 294) | P value |
|--------------------------|--------------------------|--------------------------|---------|
| **Baseline characteristics** |                          |                          |         |
| Male (n, %)              | 254 (86.4)               | 245 (83.3)               | 0.300   |
| Age (yrs, mean± SD)      | 54.9± 12.7               | 55.4± 13.8               | 0.646   |
| HBeAg positive (n, %)    | 59 (20.1)                | 68 (23.1)                | 0.367   |
| HBV-DNA positive (n, %)  | 73 (24.8)                | 77 (26.2)                | 0.070   |
| Serum ALB (g/L, mean± SD) | 32.9± 2.3                | 33.0± 2.4                | 0.570   |
| Serum TBIL (μmol/L, mean± SD) | 14.2± 4.6               | 13.7± 5.0                | 0.219   |
| Serum AFP (ng/mL, mean± SD) | 302.2± 155.3            | 338.4± 152.0             | 0.004   |
| ECOG score (n, %)        |                          |                          |         |
| 0 points                 | 119 (40.5)               | 135 (45.9)               | 0.183   |
| 1 point                  | 175 (59.5)               | 159 (54.1)               |         |
| Maximum diameter of tumor (n, %) |                  |                          |         |
| < 5 cm                   | 136 (46.3)               | 115 (39.1)               | 0.197   |
| 5-10 cm                  | 146 (49.7)               | 154 (52.4)               | 0.062   |
| > 10 cm                  | 12 (4.1)                 | 25 (8.5)                 |         |
| Number of tumors (n, %)  |                          |                          |         |
| Single                   | 228 (77.6)               | 202 (68.7)               | 0.016   |
| Multiple                 | 66 (22.4)                | 92 (31.3)                |         |
| Extent of tumor (n, %)   |                          |                          |         |
| Unilateral               | 263 (89.5)               | 244 (83.0)               | 0.023   |
| Bilateral                | 31 (10.5)                | 50 (17.0)                |         |
| Portal vein invasion (n, %) |                        |                          |         |
| Absent                   | 5 (1.7)                  | 6 (2.0)                  | 0.666   |
| Unilateral               | 191 (65.0)               | 176 (59.9)               | 0.214   |
| Bilateral or main        | 98 (33.3)                | 112 (38.1)               |         |
| Hepatic vein invasion (n, %) |                    |                          |         |
| Absent                   | 273 (92.9)               | 266 (90.5)               | 0.296   |
| Present                  | 21 (7.1)                 | 28 (9.5)                 |         |
| SOR treatment            |                          |                          |         |
| Duration of SOR (week, mean± SD) | 16.7± 4.1               | 16.3± 4.0                | 0.294   |
| Overall adverse events (n, %) | 273 (92.9)              | 281 (95.6)               | 0.158   |
| Serious adverse events (n, %) | 6 (2.0)                | 8 (2.7)                  | 0.589   |

SD: standard deviation; HBV: hepatitis B virus; ALB: albumin; TBIL: total bilirubin; AFP: α-fetoprotein; ECOG: eastern cooperative oncology group; SOR: sorafenib. Positive HBV-DNA was defined as HBV-DNA ≥ 10³ copies/ml. The patients were divided into the miR122_H group and the miR122_L group according to the median of serum miRNA-122 concentration.
In addition to SOR, regorafenib is another therapeutic agent that has been demonstrated to be effective in advanced HCC [31]. Recently, some novel immunotherapies are under investigation, such as dendritic cell vaccination, immune-modulator strategy, and immune checkpoint inhibition [31]. In order to improve the efficacy, immune therapies are also adopted in conjunction with traditional therapies [32]. However, a unique immune response in the liver favors

Table 2: Radiological response to sorafenib in the study.

| Item                        | miR122_H group (n = 294) | miR122_L group (n = 294) | P value |
|-----------------------------|--------------------------|--------------------------|---------|
| 12-week radiological response |                          |                          |         |
| Complete response (n, %)     | 4                        | 2                        | —       |
| Partial response (n, %)      | 12                       | 3                        | —       |
| Stable disease (n, %)        | 67                       | 52                       | —       |
| Progressive disease (n, %)   | 211                      | 237                      | —       |
| Intrahepatic (n, %)          | 169                      | 184                      | —       |
| Extrahepatic (n, %)          | 11                       | 20                       | —       |
| Both (n, %)                  | 31                       | 33                       | —       |
| Overall response (n, %)*     | 16 (5.4)                 | 5 (1.7)                  | 0.015   |
| Disease control (n, %)*      | 83 (28.2)                | 57 (19.4)                | 0.012   |
| 24-week radiological response|                          |                          |         |
| Complete response (n, %)     | 1                        | 0                        | —       |
| Partial response (n, %)      | 7                        | 1                        | —       |
| Stable disease (n, %)        | 19                       | 10                       | —       |
| Progressive disease (n, %)   | 267                      | 283                      | —       |
| Intrahepatic (n, %)          | 213                      | 225                      | —       |
| Extrahepatic (n, %)          | 13                       | 17                       | —       |
| Both (n, %)                  | 41                       | 41                       | —       |
| Overall response (n, %)      | 8 (2.7)                  | 1 (0.3)                  | 0.019   |
| Disease control (n, %)       | 27 (9.2)                 | 11 (3.7)                 | 0.007   |

*Overall response” was the sum of “complete response” + “partial response,” and “disease control” was the sum of “complete response” + “partial response” + “stable disease.”

Table 3: Multivariate association of radiological response and survival outcomes with serum miR-122 concentration.

| Outcomes (n) | Total (n) | Univariate HR (95%CI)* | Multivariate HR (95%CI)*b |
|--------------|-----------|------------------------|---------------------------|
| 12-week overall response |           |                        |                           |
| miR122_L group | 5         | 294                    | Reference                | Reference                |
| miR122_H group | 16        | 294                    | 3.21 (1.19~8.63)         | 3.22 (1.19~8.64)         |
| 12-week disease control |           |                        |                           |
| miR122_L group | 57        | 294                    | Reference                | Reference                |
| miR122_H group | 83        | 294                    | 1.47 (1.08~1.97)         | 1.48 (1.08~1.98)         |
| 12-week PFS |           |                        |                           |
| miR122_L group | 57        | 294                    | Reference                | Reference                |
| miR122_H group | 83        | 294                    | 1.47 (1.08~1.97)         | 1.48 (1.08~1.98)         |
| 12-week OS |           |                        |                           |
| miR122_L group | 255       | 294                    | Reference                | Reference                |
| miR122_H group | 283       | 294                    | 1.12 (1.07~1.17)         | 1.12 (1.07~1.18)         |
| 24-week overall response |           |                        |                           |
| miR122_L group | 1         | 294                    | Reference                | Reference                |
| miR122_H group | 8         | 294                    | 8.01 (1.01~63.57)        | 8.02 (1.01~63.58)        |
| 24-week disease control |           |                        |                           |
| miR122_L group | 11        | 294                    | Reference                | Reference                |
| miR122_H group | 27        | 294                    | 2.46 (1.24~4.87)         | 2.47 (1.24~4.88)         |
| 24-week PFS |           |                        |                           |
| miR122_L group | 11        | 294                    | Reference                | Reference                |
| miR122_H group | 27        | 294                    | 2.46 (1.24~4.87)         | 2.47 (1.24~4.88)         |
| 24-week OS |           |                        |                           |
| miR122_L group | 203       | 294                    | Reference                | Reference                |
| miR122_H group | 241       | 294                    | 1.19 (1.09~1.31)         | 1.20 (1.09~1.32)         |

*PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval. bThe multivariate COX model was adjusted by gender, age, annual income, HBeAg, HBV-DNA, serum albumin, serum total bilirubin, serum fetoprotein, ECOG score, maximum diameter of tumor, number of tumors, extent of tumor, portal vein invasion, and hepatic vein invasion.
tolerance, which is a challenge for immune therapies against HCC [31]. So, it is meaningful to explore some effective predictors for response to these therapies mentioned above. Based on the results from the study, we speculate that miR-122 is a potential candidate, which deserves to be explored in future studies.

In conclusion, the study demonstrated that serum miR-122 concentration was associated with radiological and survival outcomes in advanced HCC patients with SOR treatment, and the relatively higher miR-122 level in serum might predict a better response to the drug. Such prognostic significance can be affected by high HBV load or high viral activity. Further studies should be conducted to verify our conclusion.

Data Availability

Data cannot be shared because the data form part of an ongoing study.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Supplementary Materials

Supplementary Table 1: detailed data of miR-122 in RT-qPCR. (Supplementary Materials)

References

[1] A. Forner, M. Reig, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 391, no. 10127, pp. 1301–1314, 2018.
[2] R. X. Zhu, W. K. Seto, C. L. Lai, and M. F. Yuen, “Epidemiology of hepatocellular carcinoma in the Asia-Pacific region,” Gut and Liver, vol. 10, pp. 332–339, 2016.
[3] J. M. Llovet, J. Bustamante, A. Castells et al., “Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials,” Hepatology, vol. 29, no. 1, pp. 62–67, 1999.
[4] G. Cabibbo, M. Enea, M. Attanasio, J. Bruix, A. Craxi, and C. Cammà, “A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma,” Hepatology, vol. 51, no. 4, pp. 1274–1283, 2010.
[5] A.-L. Cheng, Y.-K. Kang, Z. Chen et al., “Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial,” The Lancet Oncology, vol. 10, no. 1, pp. 25–34, 2009.
[6] J. Bruix, A.-L. Cheng, G. Meinhardt, K. Nakajima, Y. De Sanctis, and J. Llovet, “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies,” Journal of Hepatology, vol. 67, no. 5, pp. 999–1008, 2017.
[7] Y.-j. Zhu, B. Zheng, H.-y. Wang, and L. Chen, “New knowledge of the mechanisms of sorafenib resistance in liver cancer,” Acta Pharmacologica Sinica, vol. 38, no. 5, pp. 614–622, 2017.
[8] G. Marisi, A. Cucchetti, P. Ulivi et al., “Ten years of sorafenib in hepatocellular carcinoma: are there any predictive and/or prognostic markers?” World Journal of Gastroenterology, vol. 24, no. 36, pp. 4152–4163, 2018.
[9] O. Brunetti, A. Gnoni, A. Licchetta et al., “Predictive and prognostic factors in HCC patients treated with sorafenib,” Medicina, vol. 55, no. 10, p. 707, 2019.
[10] Y. Ladeiro, G. Coughy, C. Balabaud et al., “MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations,” Hepatology, vol. 47, no. 6, pp. 1955–1963, 2008.
[11] V. Bihre, M. Friedrich-Rust, B. Kronenberger et al., “Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection,” American Journal of Gastroenterology, vol. 106, no. 9, pp. 1663–1669, 2011.
[12] K. Jampoka, P. Muangpaisarn, K. Khongnomman, S. Treeprasertsuk, P. Tangkijvanich, and S. Payungporn, “Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD),” Microrna, vol. 7, no. 3, pp. 215–222, 2018.
[13] C. Roderburg, B. Benz, D. Vargas Cardenas et al., “Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases,” Liver International, vol. 35, no. 4, pp. 1172–1184, 2015.
[14] S. Bai, M. W. Nasser, B. Wang et al., “MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib,” Journal of Biological Chemistry, vol. 284, no. 46, pp. 32015–32027, 2009.
[15] C. Turato, F. Fornari, D. Pollutri et al., “MiR-122 targets serpinb3 and is involved in sorafenib resistance in hepatocellular carcinoma,” Journal of Clinical Medicine, vol. 8, no. 2, p. 171, 2019.

[16] S. Bota, F. Piscaglia, S. Marinelli, A. Pecorelli, E. Terzi, and L. Bolondi, “Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma,” Liver Cancer, vol. 1, no. 3-4, pp. 190–200, 2012.

[17] I. de Kock, M. Mirhosseini, F. Lau et al., “Conversion of karnofsky performance status (KPS) and eastern cooperative oncology group performance status (ECOG) to palliative performance scale (PPS), and the interchangeability of PPS and KPS in prognostic tools,” Journal of Palliative Care, vol. 29, no. 3, pp. 163–169, 2013.

[18] H. Y. Kim, J.-W. Park, J. Joo et al., “Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma,” Journal of Gastroenterology and Hepatology, vol. 28, no. 11, pp. 1756–1761, 2013.

[19] E. A. Eisenhauer, P. Herasse, J. Bogaert et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009.

[20] G. M. Keating, “Sorafenib: a review in hepatocellular carcinoma,” Targeted Oncology, vol. 12, no. 2, pp. 243–253, 2017.

[21] G. Cabibbo, A. Cucchetti, C. Cammà et al., “Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of phase III trials,” Future Oncology, vol. 15, no. 29, pp. 3411–3422, 2019.

[22] S. Chen, Z. Peng, M. Wei et al., “Sorafenib versus transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis,” BMC Cancer, vol. 18, no. 1, p. 392, 2018.

[23] J. Rimola, À. Díaz-González, A. Darnell et al., “Complete response under sorafenib in patients with hepatocellular carcinoma: relationship with dermatologic adverse events,” Hepatology, vol. 67, no. 2, pp. 612–622, 2018.

[24] Z. Peng, S. Chen, H. Xiao et al., “Microvacular invasion as a predictor of response to treatment with sorafenib and transarterial chemoembolization for recurrent intermediate-stage hepatocellular carcinoma,” Radiology, vol. 292, no. 1, pp. 237–247, 2019.

[25] A. Casadei-Gardinì, V. Dadduzio, G. Rovesti et al., “Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib,” Medicine (Baltimore), vol. 99, no. 22, Article ID e19958, 2020.

[26] E. L. Yoon, J. E. Yeon, E. Ko et al., “An explorative analysis for the role of serum miR-10b-3p levels in predicting response to sorafenib in patients with advanced hepatocellular carcinoma,” Journal of Korean Medical Science, vol. 32, no. 2, pp. 212–220, 2017.

[27] Y.-H. Zhou, “Global prevalence of hepatitis B virus infection and prevention of mother-to-child transmission,” The Lancet Gastroenterology & Hepatology, vol. 3, no. 9, p. 598, 2018.

[28] H. Nagai, T. Mukozu, K. Kobayashi et al., “Influence of interferon on host immunity in patients with liver cirrhosis with advanced hepatocellular carcinoma stratified by etiology,” Anticancer Research, vol. 39, no. 4, pp. 2183–2191, 2019.

[29] Y. Yang, F. Wen, J. Li et al., “A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib,” Liver International, vol. 35, no. 9, pp. 2147–2154, 2015.

[30] T. Someya, K. Ikeda, S. Saitoh et al., “Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis,” Journal of Gastroenterology, vol. 41, no. 12, pp. 1206–1213, 2006.

[31] V. Longo, A. Gnoni, A. C. Gardini et al., “Immunotherapeutic approaches for hepatocellular carcinoma,” Oncotarget, vol. 8, no. 20, pp. 33897–33910, 2017.

[32] V. Longo, O. Brunetti, A. Gnoni et al., “Emerging role of immune checkpoint inhibitors in hepatocellular carcinoma,” Medicina, vol. 55, no. 10, p. 698, 2019.